Results 171 to 180 of about 85,259 (288)

Editorial: Case reports in autoimmune and autoinflammatory disorders. [PDF]

Front Immunol
Wincup C, Vaglio A, Volpi S, Ghiggeri GM.   +3 more
europepmc   +1 more source

Effect of the Arg16Gly β2‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study

Allergy, EarlyView.
This study examines the association between the rs1042713 (Arg16Gly) polymorphism of the β2‐adrenergic receptor and the risk of severe eosinophilic asthma, as well as its influence on mepolizumab long‐term effectiveness and clinical remission. The Arg16 allele is associated with increased risk of severe disease and potentially diminished long‐term ...
Santi Nolasco, Evelina Fagone, Raffaele Campisi, Andrea Portacci, Giulia Scioscia, Corrado Pelaia, Angelantonio Maglio, Claudio Candia, Vitaliano Nicola Quaranta, Isabella Carrieri, Alessandro Saglia, Alessandro Vatrella, Girolamo Pelaia, Carlo Vancheri, Maria Pia Foschino Barbaro, Maria D'Amato, Giovanna Elisiana Carpagnano, Nunzio Crimi, Claudia Crimi, on behalf of the Southern Italy Network on Severe Asthma Therapy, Rossella Intravaia, Morena Porto, Pietro Impellizzeri, Maria Provvidenza Pistorio, Fabio Vignera, Andrea Alessia Nardo, Concetta Giannì, Silvano Dragonieri, Flogerta Sana, Valeria Pezzuto, Santina Ferulli, Massimo Triggiani, Roberta Parente, Pasquale Tondo, Piera Soccio, Donato Lacedonia, Luigi Ciampo, Antonio Franzese, Valeria Longobardi   +38 more
wiley   +1 more source

Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database. [PDF]

J Pharm Health Care Sci
Tabuchi Y, Tsujimoto M, Kise Y, Sakamoto T, Matsuda M, Kosaka T, Nishiguchi K.   +6 more
europepmc   +1 more source

Drug‐Induced Periocular and Ocular Surface Disorders: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Various systemic and topical medications can induce ocular and periocular cutaneous adverse effects (AEs), ranging from mild to severe. These AEs may lead to ocular surface (OS) damage and, in some cases, life‐threatening complications. Drug‐induced ocular adverse reactions are generally classified into two primary categories: toxic reactions ...
Andrea Leonardi, Banu Bozkurt, Diana Silva, Charlotte G. Mortz, Christophe Baudouin, Marina Atanaskovic‐Markovic, Vibha Sharma, Serge Doan, Shweta Agarwal, Daniel Pérez‐Formigo, Maria Joao Vasconcelos, Francoise‐Brignole Baudouin, Gonzalo Chorzepa, Jean‐Luc Fauquert, Virginia Calder, Pascal Demoly, Luis Delgado   +16 more
wiley   +1 more source

Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates. [PDF]

Discov Nano
Dixit T, Aswini A, Nikam H, Vaidya A, Ravindran S.   +4 more
europepmc   +1 more source

Emerging role of G protein‐coupled receptor class C group 5 member D‐directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies

British Journal of Haematology, EarlyView.
Summary Multiple myeloma (MM) is a clonal malignancy of plasma cells characterized by frequent relapse and therapeutic resistance. G protein‐coupled receptor class C group 5 member D (GPRC5D) has emerged as a promising immunotherapeutic target due to its high and selective expression in MM cells and minimal presence in normal tissues.
Xueting Wang, Yushan Cui, Yaomei Wang, Baijun Fang   +3 more
wiley   +1 more source

An anti-CD47 antibody binds to a distinct epitope in a novel metal ion-dependent manner to minimize cross-linking of red blood cells. [PDF]

J Biol Chem
Lu X, Chen Z, Yi C, Ling Z, Ye J, Chen K, Cong Y, Sonam W, Cheng S, Wang R, Zhang D, Xu J, Yang J, Ma L, Duan Q, Sun X, Ding J, Sun B.   +17 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Acute Interstitial Nephritis Induced by Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)-Unveiling a New Association: A Case Report. [PDF]

Kidney Med
Vargas-Brochero MJ, Mekraksakit P, Garg AK, Fervenza FC, Zand L.   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source